A retrospective cohort study reporting rituximab treatment for 33 patients with immunobullous disease.

Nicola WatsonMarco CarrozzoPhilip J Hampton

Published in: Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology (2020)

This real clinic data adds to the evidence that Rituximab is a safe and effective treatment for both pemphigus and pemphigoid autoimmune blistering conditions. Significantly, we were able to demonstrate a substantial reduction in corticosteroid dosage in our cohort of patients following rituximab treatment.

Keyphrases

diffuse large b cell lymphoma
primary care
multiple sclerosis
ejection fraction
chronic kidney disease
deep learning
replacement therapy
big data
artificial intelligence
adverse drug
patient reported